Cargando…

Current status of theranostics in prostate cancer

The aim of this review is to report on the current status of prostate-specific membrane antigen (PSMA)-directed theranostics in prostate cancer (PC) patients. The value of (68)Ga-PSMA-directed PET imaging as a diagnostic procedure for primary and recurrent PC as well as the role of evolving PSMA rad...

Descripción completa

Detalles Bibliográficos
Autores principales:	Virgolini, Irene, Decristoforo, Clemens, Haug, Alexander, Fanti, Stefano, Uprimny, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2017
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787224/ https://www.ncbi.nlm.nih.gov/pubmed/29282518 http://dx.doi.org/10.1007/s00259-017-3882-2

Ejemplares similares

Comparison of Early Imaging and Imaging 60 min Post-Injection after Forced Diuresis with Furosemide in the Assessment of Local Recurrence in Prostate Cancer Patients with Biochemical Recurrence Referred for 68Ga-PSMA-11 PET/CT
por: Bayerschmidt, Steffen, et al.
Publicado: (2021)

Radiopharmaceutical Formulation and Preclinical Testing of (68)Ga-Labeled DOTA-MGS5 for the Regulatory Approval of a First Exploratory Clinical Trial
por: Hörmann, Anton A., et al.
Publicado: (2021)

Clinical translation of theranostic radiopharmaceuticals: Current regulatory status and recent examples
por: Kolenc Peitl, Petra, et al.
Publicado: (2019)

Third-line treatment and (177)Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review
por: von Eyben, Finn Edler, et al.
Publicado: (2017)

The current status of prostate cancer treatment and PSMA theranostics
por: Uemura, Motohide, et al.
Publicado: (2023)

(177)Lu-PSMA-617 radioligand therapy for a patient with lymph node metastatic prostate cancer
por: von Eyben, Finn E., et al.
Publicado: (2017)

Current knowledge on the sensitivity of the (68)Ga-somatostatin receptor positron emission tomography and the SUV(max) reference range for management of pancreatic neuroendocrine tumours
por: Virgolini, Irene, et al.
Publicado: (2016)

Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms
por: Fani, Melpomeni, et al.
Publicado: (2017)

Highlights of the 30th Annual Congress of the EANM, Vienna 2017: “Yes we can – make nuclear medicine great again”
por: Fanti, Stefano, et al.
Publicado: (2018)

PSMA Theranostics: Current Status and Future Directions
por: Rahbar, Kambiz, et al.
Publicado: (2018)

Update of PSMA Theranostics in Prostate Cancer: Current Applications and Future Trends
por: Kaewput, Chalermrat, et al.
Publicado: (2022)

Imaging Properties and Tumor Targeting of (68)Ga-NeoBOMB1, a Gastrin-Releasing Peptide Receptor Antagonist, in GIST Patients
por: Gruber, Leonhard, et al.
Publicado: (2022)

Siderophore-Based Molecular Imaging of Fungal and Bacterial Infections—Current Status and Future Perspectives
por: Petrik, Milos, et al.
Publicado: (2020)

Enhancing Clinical Diagnosis for Patients With Persistent Pulmonary Abnormalities After COVID-19 Infection: The Potential Benefit of (68)Ga-FAPI PET/CT
por: Sviridenko, Anna, et al.
Publicado: (2022)

Preliminary Findings of the Role of FAPi in Prostate Cancer Theranostics
por: Laudicella, Riccardo, et al.
Publicado: (2023)

Long-Term Survival and Value of (18)F-FDG PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with Second Peptide Receptor Radionuclide Therapy Course with (177)Lu-DOTATATE
por: Rodrigues, Margarida, et al.
Publicado: (2021)

The (68)Ga/(177)Lu-theragnostic concept in PSMA-targeting of metastatic castration–resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up
por: Maffey-Steffan, Johanna, et al.
Publicado: (2019)

Biomolecule-functionalized nanoformulations for prostate cancer theranostics
por: Pranav, et al.
Publicado: (2022)

PSMA-Targeting Imaging and Theranostic Agents—Current Status and Future Perspective
por: Debnath, Sashi, et al.
Publicado: (2022)

[(68)Ga]NODAGA-RGD – Metabolic stability, biodistribution, and dosimetry data from patients with hepatocellular carcinoma and liver cirrhosis
por: Haubner, Roland, et al.
Publicado: (2016)

Prostate Cancer Theranostics - An Overview
por: Abou, Diane, et al.
Publicado: (2020)

PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy
por: Jones, Wallace, et al.
Publicado: (2020)

Current State of Breast Cancer Diagnosis, Treatment, and Theranostics
por: Bhushan, Arya, et al.
Publicado: (2021)

The Current Status and Future Potential of Theranostics to Diagnose and Treat Childhood Cancer
por: Poot, Alex J., et al.
Publicado: (2020)

Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer
por: Plichta, Kristin A., et al.
Publicado: (2021)

Current status of contemporary diagnostic radiotracers in the management of breast cancer: first steps toward theranostic applications
por: Altena, Renske, et al.
Publicado: (2023)

Optimizing PSMA Radioligand Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Meta-Analysis
por: von Eyben, Finn Edler, et al.
Publicado: (2020)

Antifungal Siderophore Conjugates for Theranostic Applications in Invasive Pulmonary Aspergillosis Using Low-Molecular TAFC Scaffolds
por: Pfister, Joachim, et al.
Publicado: (2021)

MicroRNAs as Biomarkers for Diagnosis, Prognosis and Theranostics in Prostate Cancer
por: Bertoli, Gloria, et al.
Publicado: (2016)

The State of the Art of Theranostic Nanomaterials for Lung, Breast, and Prostate Cancers
por: Freitas, Lucas F., et al.
Publicado: (2021)

Tunable Plasmonic Nanoprobes for Theranostics of Prostate Cancer
por: Lukianova-Hleb, Ekaterina Y., et al.
Publicado: (2011)

Current Status of Biomarkers for Prostate Cancer
por: Velonas, Vicki M., et al.
Publicado: (2013)

Advanced nanomaterial for prostate cancer theranostics
por: Hao, Bin, et al.
Publicado: (2022)

Biomarkers in Prostate-Specific Membrane Antigen Theranostics
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2021)

Current Status of Brachytherapy for Prostate Cancer
por: Park, Dong Soo
Publicado: (2012)

PSMA Theranostics: Current Landscape and Future Outlook
por: Zhang, Hanbo, et al.
Publicado: (2021)

Retraction of “Tunable Plasmonic Nanoprobes for Theranostics of Prostate Cancer”
por: Lukianova-Hleb, Ekaterina Y., et al.
Publicado: (2017)

Influence of a novel, versatile bifunctional chelator on theranostic properties of a minigastrin analogue
por: Pfister, Joachim, et al.
Publicado: (2015)

Bi-insular cortical involvement in anti-NMDA-receptor encephalitis – a case report
por: Hegen, Harald, et al.
Publicado: (2016)

Focal therapy for prostate cancer: The current status
por: Marshall, Susan, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_s4t876snr7t7f2p0acrn6t1a0r